AKRO
Akero Therapeutics Inc

2,220
Mkt Cap
$4.47B
Volume
1.85M
52W High
$58.40
52W Low
$21.34
PE Ratio
-14.49
AKRO Fundamentals
Price
$54.20
Prev Close
$54.30
Open
$54.25
50D MA
$49.71
Beta
0.94
Avg. Volume
3.77M
EPS (Annual)
-$3.75
P/B
4.54
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Nan Fung Trinity HK Ltd. Invests $5.90 Million in Akero Therapeutics, Inc. $AKRO
Nan Fung Trinity HK Ltd. purchased a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the...
MarketBeat·12h ago
News Placeholder
More News
News Placeholder
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...
PR Newswire·1d ago
News Placeholder
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) Berger Montague PC...
PR Newswire·1d ago
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...
PR Newswire·3d ago
News Placeholder
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith
Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.
Stocktwits·4d ago
News Placeholder
Akero Therapeutics (NASDAQ:AKRO) Releases Quarterly Earnings Results
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·5d ago
News Placeholder
Akero Therapeutics (AKRO) Projected to Post Earnings on Friday
Akero Therapeutics (NASDAQ:AKRO) will be releasing its Q3 2025 earnings before the market opens on Friday, November 14. (View Earnings Report at...
MarketBeat·7d ago
News Placeholder
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) Berger Montague PC...
PR Newswire·15d ago
News Placeholder
Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their...
PR Newswire·15d ago
News Placeholder
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates EA, HSII, AKRO on Behalf of Shareholders PR...
PR Newswire·1mo ago

Latest AKRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.